As of 2025-09-18, the Intrinsic Value of Jazz Pharmaceuticals PLC (JAZZ) is 118.19 USD. This JAZZ valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 131.19 USD, the upside of Jazz Pharmaceuticals PLC is -9.90%.
The range of the Intrinsic Value is 57.34 - 317.78 USD
Based on its market price of 131.19 USD and our intrinsic valuation, Jazz Pharmaceuticals PLC (JAZZ) is overvalued by 9.90%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 57.34 - 317.78 | 118.19 | -9.9% |
| DCF (Growth 10y) | 89.38 - 392.42 | 160.73 | 22.5% |
| DCF (EBITDA 5y) | 48.73 - 111.00 | 76.66 | -41.6% |
| DCF (EBITDA 10y) | 76.09 - 156.44 | 111.01 | -15.4% |
| Fair Value | -79.51 - -79.51 | -79.51 | -160.61% |
| P/E | (209.83) - 144.31 | (62.71) | -147.8% |
| EV/EBITDA | 58.67 - 241.93 | 144.89 | 10.4% |
| EPV | 105.95 - 170.14 | 138.04 | 5.2% |
| DDM - Stable | (47.02) - (132.13) | (89.57) | -168.3% |
| DDM - Multi | 43.23 - 96.64 | 59.98 | -54.3% |
| Market Cap (mil) | 7,957.99 |
| Beta | 0.97 |
| Outstanding shares (mil) | 60.66 |
| Enterprise Value (mil) | 12,132.19 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.24% |
| Cost of Debt | 7.35% |
| WACC | 8.28% |